AUTL - オ―トルス・セラピュ―ティクス (Autolus Therapeutics plc)

AUTLのニュース

   Autolus'' Blood Cancer CAR T-Cell Therapy Receives Promising Innovative Medicine In UK  2021/08/09 15:57:11 Benzinga
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation to Autolus Therapeutics plc''s (NASDAQ: AUTL ) AUTO1 (obecabtagene Full story available on Benzinga.com
   Autolus Therapeutics plc 2021 Q2 - Results - Earnings Call Presentation  2021/08/06 16:10:34 Seeking Alpha
   Autolus Stock Jumps On Cancer mRNA Therapeutics Agreement With Moderna  2021/08/02 12:48:57 Benzinga
Autolus Therapeutics plc (NASDAQ: AUTL ) has granted Moderna Inc (NASDAQ: MRNA ) an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus'' proprietary Full story available on Benzinga.com
   Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer  2021/07/15 11:00:00 Intrado Digital Media
LONDON, July 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Edgar Braendle M.D., Ph.D., as chief development officer. Dr Braendle is joining Autolus executive team today and will lead the company''s development organization.
   Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021  2021/07/08 11:00:00 Intrado Digital Media
LONDON, July 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2021 financial results and operational highlights before open of U.S. markets on Thursday, August 5, 2021.
   Autolus Announces Appointment of Edgar Braendle, M.D., Ph.D., as Chief Development Officer  2021/07/15 11:00:00 Intrado Digital Media
LONDON, July 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Edgar Braendle M.D., Ph.D., as chief development officer. Dr Braendle is joining Autolus executive team today and will lead the company''s development organization.
   Autolus Therapeutics to Report Second Quarter 2021 Financial Results on August 5, 2021, and will Participate in the William Blair Biotech Focus Conference 2021 on July 14, 2021  2021/07/08 11:00:00 Intrado Digital Media
LONDON, July 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2021 financial results and operational highlights before open of U.S. markets on Thursday, August 5, 2021.
   Autolus Therapeutics'' obe-cel shows high clinical activity in blood cancers, shares rise 5%  2021/06/11 11:39:37 Seeking Alpha
   Autolus Therapeutics Announces an Additional Nature Publication for AUTO1- Data suggest that long term durability of response in acute lymphoblastic leukemia patients treated with AUTO1 is due to an enrichment of Stem Cell Memory T cells -  2021/05/25 00:00:00 BioSpace
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced a publication in Nature Cancer that gives new insight into the mechanism of long-term durability of effect in acute lymphoblastic leukemia patients treated with AUTO1.
   Autolus Notice of Annual General Meeting (AGM) on Friday, June 18, 2021  2021/05/21 00:00:00 BioSpace
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, posted notice of its Annual General Meeting to shareholders, which can be viewed and downloaded from www.autolus.com.
   Autolus Therapeutics'' obe-cel shows high clinical activity in blood cancers, shares rise 5%  2021/06/11 11:39:37 Seeking Alpha
   Autolus Therapeutics Announces an Additional Nature Publication for AUTO1- Data suggest that long term durability of response in acute lymphoblastic leukemia patients treated with AUTO1 is due to an enrichment of Stem Cell Memory T cells -  2021/05/25 00:00:00 BioSpace
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced a publication in Nature Cancer that gives new insight into the mechanism of long-term durability of effect in acute lymphoblastic leukemia patients treated with AUTO1.
   Autolus Notice of Annual General Meeting (AGM) on Friday, June 18, 2021  2021/05/21 00:00:00 BioSpace
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, posted notice of its Annual General Meeting to shareholders, which can be viewed and downloaded from www.autolus.com.
   Opaleye Management Inc. Buys BridgeBio Pharma Inc, Autolus Therapeutics PLC, Gemini ...  2021/05/19 16:38:07 GuruFocus
Related Stocks: MGNX , AVEO , CBIO , KNSA , OPTN , SRRA , BBIO , AUTL , GMTX , KROS ,
   Autolus gains after announcing 100 percent complete remission in blood cancer trial  2021/05/12 17:55:08 Seeking Alpha

calendar